Stockscreener 앱 받기
1.62
1.22%
-0.02
시간 외 거래:
1.63
0.010
+0.62%
전일 마감가:
$1.64
열려 있는:
$1.64
하루 거래량:
241.07K
Relative Volume:
1.48
시가총액:
$16.76M
수익:
$1.65M
순이익/손실:
$-5.66M
주가수익비율:
-1.3729
EPS:
-1.18
순현금흐름:
-
1주 성능:
-18.18%
1개월 성능:
-71.48%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$1.6001
$1.79
1주일 범위
$1.51
$2.191
52주 변동 폭
$1.51
$14.09
20 20 Biolabs Inc Stock (AIDX) Company Profile
Compare AIDX vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AIDX
20 20 Biolabs Inc
|
1.62 | 16.97M | 1.65M | -5.66M | 0 | -1.18 |
ABT
Abbott Laboratories
|
104.83 | 180.82B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
327.65 | 125.72B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
87.89 | 111.16B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
69.78 | 101.28B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
82.67 | 47.45B | 6.07B | 1.06B | 1.34B | 1.8063 |
20 20 Biolabs Inc 주식(AIDX)의 최신 뉴스
20/20 BioLabs licenses kidney disease prediction technology from ROKIT Healthcare - MSN
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
20/20 BioLabs enters exclusive technology license, access agreement with Rokit - TipRanks
What's Going On With 20/20 Biolabs Stock? - Benzinga
20/20 Biolabs Faces Decline Amid Market Rut - timothysykes.com
20/20 BioLabs licenses kidney disease prediction technology - Investing.com
20/20 BioLabs Announces Exclusive U.S. License Agreement with ROKIT Healthcare to Integrate Advanced CKD Prediction Technology into Its Longevity Test Program - The Manila Times
Kidney disease risk check joins 20/20 BioLabs longevity test - Stock Titan
What is the current Price Target and Forecast for 20/20 Biolabs Inc. (AIDX) - Zacks Investment Research
What date does 20/20 Biolabs Inc.'s (AIDX) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
AIDX Stock Price, News & Analysis - Stock Titan
Debt to equity ratio of 20/20 Biolabs, Inc. – NASDAQ:AIDX - TradingView
AIDX: 20/20 Biolabs Inc.Options Chain - Zacks Investment Research
20/20 Biolabs Inc. (AIDX) Total Long Term Debt (Quarterly) - Zacks Investment Research
20/20 Biolabs Inc. (AIDX) Return On Assets (TTM) - Zacks Investment Research
20/20 Biolabs Inc. (AIDX) Total Expenses (TTM) - Zacks Investment Research
20/20 Biolabs Inc. (AIDX) Price Book Value - Zacks Investment Research
Cash per share of 20/20 Biolabs, Inc. – NASDAQ:AIDX - TradingView
Michael A. Ross Net Worth (2026) - GuruFocus
Michael Saul Lebowitz Net Worth (2026) - GuruFocus
Jonathan M Cohen Net Worth (2026) - GuruFocus
Prasanth Reddy Net Worth (2026) - GuruFocus
Jiming Zhou Net Worth (2026) - GuruFocus
20/20 BioLabs Highlights Advantages of its Patented Protein Biomarker Technology for Multi-Cancer Early Detection in Light of Recent Studies - Sahm
20/20 Biolabs, Inc. Revenue Breakdown – NASDAQ:AIDX - TradingView
Analysts Offer Insights on Healthcare Companies: 20/20 Biolabs, Inc. (AIDX) and Biogen (BIIB) - The Globe and Mail
20/20 BioLabs provides update on protein biomarket technology for MCED - TipRanks
Jonathan Cohen Discloses Investment at 20/20 Biolabs with 16.8% Stake - TradingView
20/20 Biolabs (NASDAQ: AIDX) CEO holds 16.8% stake in company - Stock Titan
20/20 Biolabs (AIDX) CEO awarded 352,936-share stock option grant - Stock Titan
20/20 Biolabs Inc. (AIDX) Revenue (Quarterly) Yoy Growth - Zacks Investment Research
20/20 Biolabs (AIDX) 10K Form and SEC Filings 2026 - MarketBeat
20/20 Biolabs Inc. (AIDX) Free Cash Flow (TTM) - Zacks Investment Research
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
20/20 Biolabs Inc. (AIDX) Price To Cash Flow - Zacks Investment Research
20/20 Biolabs Inc. (AIDX) Net Income (Quarterly) - Zacks Investment Research
AIDX News Today | Why did 20/20 Biolabs stock go down today? - MarketBeat
20/20 Biolabs (AIDX) Stock Price, News & Analysis - MarketBeat
20/20 Biolabs Inc. (AIDX) Cash From Operations (TTM) - Zacks Investment Research
Number of employees of 20/20 Biolabs, Inc. – NASDAQ:AIDX - TradingView
20/20 Biolabs Inc. (AIDX) Cash From Financing (TTM) - Zacks Investment Research
20/20 Biolabs Inc. (AIDX) Dividend Yield (TTM) - Zacks Investment Research
20/20 Biolabs Inc. (AIDX) Shareholders Equity (Quarterly) - Zacks Investment Research
20/20 Biolabs Inc. (AIDX) Revenue (Quarterly) - Zacks Investment Research
20/20 Biolabs Inc. (AIDX) Profit Margin (Quarterly) - Zacks Investment Research
20/20 Biolabs Inc. (AIDX) Revenue (TTM) - Zacks Investment Research
20/20 Biolabs Inc. (AIDX) - Zacks Investment Research
20/20 Biolabs Inc. (AIDX) Total Assets (Quarterly) - Zacks Investment Research
20/20 Biolabs Inc. (AIDX) Ps Ratio (TTM) - Zacks Investment Research
20/20 Biolabs, Inc. Common Stock (AIDX) Competitors - Meyka
20/20 Biolabs, Inc. Common Stock (AIDX) AI-Powered Stock Analysis - Meyka
20 20 Biolabs Inc (AIDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.53%
자본화:
|
볼륨(24시간):